

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2014

Vol. 42, No. 9

CONTENTS

SHORT COMMUNICATIONS

Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell-Derived Hepatocytes. *Gustav Holmgren, Anna-Karin Sjögren, Isabel Barragan, Alan Sabirsh, Peter Sartipy, Jane Synnergren, Petter Björquist, Magnus Ingelman-Sundberg, Tommy B. Andersson, and Josefina Edsbacke* **1401**

Polymorphisms of *CYP2D17* in Cynomolgus and Rhesus Macaques: an Evidence of the Genetic Basis for the Variability of CYP2D-Dependent Drug Metabolism. *Yasuhiro Uno, Shotaro Uehara, Sakae Kohara, Norie Murayama, and Hiroshi Yamazaki* **1407**

Regioselective Hydroxylation of Omeprazole Enantiomers by Bacterial CYP102A1 Mutants. *Sang Hoon Ryu, Bo-Yeon Park, So-Young Kim, Sun-Ha Park, Hyun-Jin Jung, Min Park, Ki Deok Park, Taeho Ahn, Hyung-Sik Kang, and Chul-Ho Yun* **1493**

ARTICLES

Flavonoids Are Inhibitors of Human Organic Anion Transporter 1 (OAT1)-Mediated Transport. *Guohua An, Xiaodong Wang, and Marilyn E. Morris* **1357**

Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-Mediated Phosphorylation. *Nelleke Snelder, Bart A. Ploeger, Olivier Luttringer, Donald. R. Stanski, and Meindert Danhof* **1367**

Evaluation of Calibration Curve-Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes. *J. George Zhang, Thuy Ho, Alanna L. Callendrello, Robert J. Clark, Elizabeth A. Santone, Sarah Kinsman, Deqing Xiao, Lisa G. Fox, Heidi J. Einolf, and David M. Stresser* **1379**

A Potential Role for Human UDP-Glucuronosyltransferase 1A4 Promoter Single Nucleotide Polymorphisms in the Pharmacogenomics of Tamoxifen and Its Derivatives. *Aleksandra K. Greer, Centdrika R. Dates, Athena Starlard-Davenport, Vineetha K. Edavana, Stacie M. Bratton, Ishwori B. Dhakal,*

Moshe Finel, Susan A. Kadlubar, and Anna Radomska-Pandya **1392**

Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo. *Agnès Poirier, Anne-Christine Cascais, Urs Bader, Renée Portmann, Marie-Elise Brun, Isabelle Walter, Alexander Hillebrecht, Mohammed Ullah, and Christoph Funk* **1411**

Inflammatory Bowel Disease Alters Intestinal Bile Acid Transporter Expression. *Jörg Jahnel, Peter Fickert, Almuthe C. Hauer, Christoph Högenauer, Alexander Avian, and Michael Trauner* **1423**

Identification and Functional Characterization of Novel Nonsynonymous Variants in the Human Multidrug and Toxin Extrusion 2-K. *Kenta Nishimura, Ryosuke Ide, Takeshi Hirota, Kana Kawazu, Sho Kodama, Hiroaki Takesue, and Ichiro Ieiri* **1432**

Time- and NADPH-Dependent Inhibition of Cytochrome P450 3A4 by the Cyclopentapeptide Cilengitide: Significance of the Guanidine Group and Accompanying Spectral Changes. *Mirza Bojić, Luca Barbero, Hugues Dolgos, Achim Freisleben, Dieter Galleman, Simona Riva, and F. Peter Guengerich* **1438**

Nicotine Pharmacokinetics in Rats Is Altered as a Function of Age, Impacting the Interpretation of Animal Model Data. *Evelyn L. Craig, Bin Zhao, Jason Z. Cui, Maria Novalen, Sharon Miksys, and Rachel F. Tyndale* **1447**

A Strategy for Assessing Potential Drug-Drug Interactions of a Concomitant Agent against a Drug Absorbed via an Intestinal Transporter in Humans. *Akiko Mizuno-Yasuhiro, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa, and Jun-ichi Yamaguchi* **1456**

The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug

Continued on next page

- Discovery and Development: Why, When, and How?. *Agnès Poirier, Renée Portmann, Anne-Christine Cascais, Urs Bader, Isabelle Walter, Mohammed Ullah, and Christoph Funk*. **1466**
- ☐ Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations. *Khaled Abduljalil, Theresa Cain, Helen Humphries, and Amin Rostami-Hodjegan*. **1478**
- Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity. *Ikuo Yamamiya, Kunihiro Yoshisue, Yuji Ishii, Hideyuki Yamada, and Masato Chiba*. **1485**
- Characterization of Arachidonic Acid Metabolism by Rat Cytochrome P450 Enzymes: The Involvement of CYP1As. *Ahmed A. El-Sherbeni and Ayman O.S. El-Kadi*. **1498**
- ☐ Gut Microbiota-Mediated Drug Interactions between Lovastatin and Antibiotics. *Dae-Hyoung Yoo, In Sook Kim, Thi Kim Van Le, Il-Hoon Jung, Hye Hyun Yoo, and Dong-Hyun Kim*. **1508**
- Prediction of Organic Anion-Transporting Polypeptide 1B1- and 1B3-Mediated Hepatic Uptake of Statins Based on Transporter Protein Expression and Activity Data. *Annett Kunze, Jörg Huwyler, Gian Camenisch, and Birk Poller*. **1514**
- ☐ Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs. *Haruka Nishimuta, J. Brian Houston, and Aleksandra Galetin*. **1522**
- Dynamic and Coordinated Regulation of KEAP1-NRF2-ARE and p53/p21 Signaling Pathways Is Associated with Acetaminophen Injury Responsive Liver Regeneration. *Xiaomei Fan, Pan Chen, Huasen Tan, Hang Zeng, Yiming Jiang, Ying Wang, Yongtao Wang, Xiangyu Hou, Huichang Bi, and Min Huang*. **1532**
- ☐ A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes. *Tetsuya Mitsui, Takayuki Nemoto, Taiji Miyake, Shunsuke Nagao, Kotaro Ogawa, Motohiro Kato, Masaki Ishigai, and Hideyuki Yamada*. **1540**
- Interindividual Variations in Metabolism and Pharmacokinetics of 3-(6-Methylpyridine-3-yl-sulfanyl)-6-(4H-[1,2,4]triazole-3-yl-sulfanyl)-N-(1,3-thiazole-2-yl)-2-pyridine carboxamide, a Glucokinase Activator, in Rats Caused by the Genetic Polymorphism of CYP2D1. *Takuro Hasegawa, Jun-ichi Eiki, and Masato Chiba*. **1548**
- ☐ Impact of Inflammation on Chlorpromazine-Induced Cytotoxicity and Cholestatic Features in HepaRG Cells. *Pamela Bachour-El Azzi, Ahmad Sharanek, Ziad Abdel-Razzak, Sebastien Antherieu, Houssein Al-Attrache, Camille C. Savary, Sylvie Lepage, Isabelle Morel, Gilles Labbe, Christiane Guguen-Guillouzo, and André Guillouzo*. **1556**
- Role of Multidrug Resistance–Associated Protein 4 in the Basolateral Efflux of Hepatically Derived Enalaprilat. *Brian C. Ferslew, Kathleen Köck, Arlene S. Bridges, and Kim L. R. Brouwer*. **1567**
- ☐ A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 1. Theoretical Considerations. *Swati Nagar, Jeffrey P. Jones, and Ken Korzekwa*. **1575**
- A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data. *Ken Korzekwa, Donald Tweedie, Upendra A. Argikar, Andrea Whitcheer-Johnstone, Leslie Bell, Shari Bickford, and Swati Nagar*. **1587**

ERRATUM

- Correction to “Enhanced Nicotine Metabolism in HIV-1–Positive Smokers Compared with HIV-Negative Smokers: Simultaneous Determination of Nicotine and its Four Metabolites in Their Plasma Using a Simple and Sensitive Electrospray Ionization Liquid Chromatography–Tandem Mass Spectrometry Technique”. **1596**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: The structural model of human MATE2-K is presented - side view. See the article by Nishimura et al., ([dx.doi.org/10.1124/dmd.114.056887](https://doi.org/10.1124/dmd.114.056887)).